


Novo Seeds




OUR STRUCTURE




If you wish to learn more about the Novo Nordisk Foundation, Novo A/S or any of our other investment units, go to www.novo.dk

Novo Seeds – part of a continuous financing chain



Our programs



What do we invest in?

▪ **Sectors**

- Drug discovery and development
 - Biologics
 - Small molecules
 - Vaccines
 - Platform technologies
 - Opportunistic on Therapy Areas - no link to Novo Nordisk areas of interest
- Medical devices
- Diagnostics & life science
- Industrial Biotechnology

▪ **Business Model**


- Lean & virtual set-up
- University spin outs
- Pharma spin outs
- Repurposing opportunities

▪ **Geography**


- Nordic region

Geographical overview of Novo Seeds portfolio

— Seed companies
— Pre-Seed projects



The seed portfolio: centered around lead optimisation and pre-clinical development



What does Novo Seeds offer?

Novo Seeds as partner

- Portfolio of top-tier Nordic biotech companies
- Active investor anchored in an evergreen fund structure
- Investment team with extensive experience and business know-how
- Solid network to specialists in the pharma- and biotech industry
- Significant amount of capital to invest
- International network

Investment model

- Possibility to mature and qualify companies with the pre-seed program
- Grant programs de-risk investments and provide proprietary deal flow
- Financing chain allows follow-on investments
- Dedicated focus on international syndication

Feel free to contact us



Søren Møller, PhD, Managing Investment Director
 Background: Post doctoral fellow at Stanford University.
 Chief Scientific Officer, Exiqon and Head of Bioinformatics and Genomics, NovozymesA/S
 Board member Denator AB and Reapplix
smq@novo.dk



Henriette Richter, PhD, Investment Director
 Background: Postdoctoral fellow, at MIT and Director Scientific analysis, SunStone Capital
 BoD member: EpiTherapeutics, Cytoguide, Avilex Pharma and Orphazyme
heri@novo.dk



Stephan Christgau, PhD, Investment Director
 Background: Post doc at UCSF. Reserach scientist at Novo Nordisk. Project leader Nordic Bioscience, COO Osteologix
 BoD member: Aros Pharma (chair), Adenium, Galecto, Pcovery and Thrombologic (chair)
scga@novo.dk



Bobby Soni, PhD, Principal
 Background: PhD from University of Virginia, Principal Scientist at Maxygen and Disc. Licens. Manager, LEO Pharma
 BoD member: Acesion Pharma (chair), Concit Pharma and C10 Pharma
bygs@novo.dk



Nanna Lüneborg, PhD, MBA, Principal
 Background: PhD from University College, London. MBA from University of Cambridge, and Associate, Apposite Capital.
 BoD Observer: Galecto Biotech and Avilex Pharma
nllb@novo.dk



Berit Mikkelsen, HD(IB), Coordinator
 Background: Biotechnologist, HTS/UCPH. BSc International Business from Copenhagen Business School.
 Observer: Novo Nordisk Foundation Exploratory Pre-seed Grant Committee.
bmkk@novo.dk